{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:30:21Z","timestamp":1775925021825,"version":"3.50.1"},"posted":{"date-parts":[[2023,6,5]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":30,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Both vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. However, adenoviral vectored (AdV) vaccines may be less immunogenic than mRNA vaccines against SARS-CoV-2. We assessed anti-spike and anti-vector immunity among infection-na\u00efve Health Care Workers (HCW) following two doses of AdV (AZD1222) versus mRNA (BNT162b2) vaccine. 183 AdV and 274 mRNA vaccinees enrolled between April and October 2021. Median ages were 42 and 39 years, respectively. Blood was collected at least once, 10-48 days after vaccine dose 2. Surrogate virus neutralization test (sVNT) and spike binding antibody titres were a median of 4.2 and 2.2 times lower, respectively, for AdV compared to mRNA vaccinees (p&lt;0.001). Median percentages of memory B cells that recognized fluorescent-tagged spike and RBD were 2.9 and 8.3 times lower, respectively for AdV compared to mRNA vaccinees. Titres of IgG reactive with human Adenovirus type 5 hexon protein rose a median of 2.2-fold after AdV vaccination but were not correlated with anti-spike antibody titres. Together the results show that mRNA induced substantially more sVNT antibody than AdV vaccine due to greater B cell expansion and targeting of the RBD. Pre-existing AdV vector cross-reactive antibodies were boosted following AdV vaccination but had no detectable effect on immunogenicity.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Key points<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>mRNA SARS-CoV-2 vaccine induced higher surrogate neutralizing antibody titres than adenoviral vaccine<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>mRNA vaccine induced a more potent, RBD-targeted B cell response than AdV vaccine<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Adenoviral vaccine boosted antibodies against human Adenovirus, but titres don\u2019t correlate with anti-spike titres<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>","DOI":"10.1101\/2023.06.02.23290871","type":"posted-content","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:30:21Z","timestamp":1685975421000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19"],"prefix":"10.64898","author":[{"given":"Yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephany","family":"S\u00e1nchez-Ovando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Carolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Dowson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arseniy","family":"Khvorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hadiprodjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeu Yang","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Delahunty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameneh","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Macnish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Hagenauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marti","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suja","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Koirala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Kucharski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena G.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023060719251030000_2023.06.02.23290871v1.1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2023060719251030000_2023.06.02.23290871v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31604-4"},{"key":"2023060719251030000_2023.06.02.23290871v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2023060719251030000_2023.06.02.23290871v1.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"2023060719251030000_2023.06.02.23290871v1.5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2023060719251030000_2023.06.02.23290871v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"2023060719251030000_2023.06.02.23290871v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00432-3"},{"key":"2023060719251030000_2023.06.02.23290871v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2105290"},{"key":"2023060719251030000_2023.06.02.23290871v1.9","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060719251030000_2023.06.02.23290871v1.10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","year":"2022","journal-title":"Science"},{"key":"2023060719251030000_2023.06.02.23290871v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2023060719251030000_2023.06.02.23290871v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"2023060719251030000_2023.06.02.23290871v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1"},{"key":"2023060719251030000_2023.06.02.23290871v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01694-9"},{"key":"2023060719251030000_2023.06.02.23290871v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.12.006"},{"key":"2023060719251030000_2023.06.02.23290871v1.16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-022-00455-3","article-title":"Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines","volume":"7","year":"2022","journal-title":"NPJ Vaccines"},{"key":"2023060719251030000_2023.06.02.23290871v1.17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-021-02231-x","article-title":"Humoral immune response after different SARS-CoV-2 vaccination regimens","volume":"20","year":"2022","journal-title":"BMC Med"},{"key":"2023060719251030000_2023.06.02.23290871v1.18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.797589"},{"key":"2023060719251030000_2023.06.02.23290871v1.19","doi-asserted-by":"publisher","DOI":"10.1017\/S1744133121000244"},{"key":"2023060719251030000_2023.06.02.23290871v1.20","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/21645515.2017.1419108","article-title":"Development of novel vaccine vectors: Chimpanzee adenoviral vectors","volume":"14","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2023060719251030000_2023.06.02.23290871v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0631-z"},{"key":"2023060719251030000_2023.06.02.23290871v1.22","doi-asserted-by":"crossref","first-page":"eadf1421","DOI":"10.1126\/sciimmunol.adf1421","article-title":"SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines","volume":"7","year":"2022","journal-title":"Sci Immunol"},{"key":"2023060719251030000_2023.06.02.23290871v1.23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"2023060719251030000_2023.06.02.23290871v1.24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2023060719251030000_2023.06.02.23290871v1.25","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"2023060719251030000_2023.06.02.23290871v1.26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S2213-2600(22)00163-1","article-title":"Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial","volume":"10","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2023060719251030000_2023.06.02.23290871v1.27","doi-asserted-by":"crossref","first-page":"100898","DOI":"10.1016\/j.xcrm.2022.100898","article-title":"Impact of SARS-CoV-2 exposure history on the T cell and IgG response","volume":"4","year":"2023","journal-title":"Cell Rep Med"},{"key":"2023060719251030000_2023.06.02.23290871v1.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2115481"},{"key":"2023060719251030000_2023.06.02.23290871v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01358-1"},{"key":"2023060719251030000_2023.06.02.23290871v1.30","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41467-022-29159-x","article-title":"Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50","volume":"13","year":"2022","journal-title":"Nat Commun"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.06.02.23290871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:34:54Z","timestamp":1768505694000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.06.02.23290871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1101\/2023.06.02.23290871","relation":{},"subject":[],"published":{"date-parts":[[2023,6,5]]},"subtype":"preprint"}}